Dr. Gerald Crabtree, Chief Operating Officer and Director at PharmaCyte Biotechnology, a clinical stage biotechnology company focused on developing targeted treatments for cancer and diabetes using its signature live-cell encapsulation technology, Cell-in-a-Box joins eHealth Radio and the Diabetes and Health News Channels.Listen to interview with host Eric Michaels and guest Dr. Gerald Crabtree discuss the following:
- In an effort to understand how the Melligen cells works, can you explain what happens to the pancreas in Type 1 diabetes?
- Why are liver cells such good candidates to replace the damaged cells in the pancreas?
- What have early lab trials shown?
- How does PharmaCyte’s Cell-in-the-Box help the melligen cells do their jobs?
- How will this technology help the lives of those patients living with Type 1 Diabetes
Dr. Gerald Crabtree is PharmaCyte’s Chief Operating Officer. Since 1985, Dr. Crabtree has been involved with various biopharmaceutical companies where he has alternatively supervised and coordinated the development of multiple drug candidates, prepared clinical protocols, investigator brochures, monographs, and research and review articles and served as project manager for development of major oncologic agents. He is a Member of the American Society of Clinical Oncology and also is a past member of research grant review committees for the National Institute of Health and the American Cancer Society. Dr. Crabtree established and directed, from inception, a department that monitored and coordinated the development of oncologic and immunologic drugs from initial discovery through regulatory approval in a major pharmaceutical company and served as project manager for the development of the anticancer agent, Taxol®.
Dr. Crabtree received his Ph.D. in Biochemistry from the University of Alberta, Edmonton, Alberta, Canada and has published over 80 articles in peer-reviewed journals. He is a National Cancer Institute of Canada Research Fellow. In addition, he served as Department Head of Molecular Pharmacology for the Nucleic Acid Research Institute, and prior to that as Associate Professor of Medicine with the Roger Williams Cancer Center at Brown University. Dr. Crabtree has also served as Director of Project Planning and Management (Oncology/Immunology) at Bristol-Myers Squibb and as Vice-President of Research and Development at ETEX Corporation.
